FDA expands access to drug helping pancreatic cancer patients
The FDA has expanded access to daraxonrasib, an investigational drug for metastatic pancreatic cancer, under its compassionate use program. The drug, taken three times daily, has shown promise in clinical trials by significantly reducing tumor volume and extending survival. Former Sen. Ben Sasse, a trial participant, described it as a "miracle drug" that has reduced his pain and tumor size.
- ▪Daraxonrasib is a pill taken three times a day that blocks signals causing cancer cells to grow uncontrollably.
- ▪In a clinical trial, patients taking daraxonrasib survived a median of 13 months compared to six months for those on chemotherapy.
- ▪The FDA approved the expanded access request from Revolution Medicine within two days of submission.
- ▪Patients with previously treated metastatic pancreatic ductal adenocarcinoma and no other options are eligible for the drug.
- ▪Pancreatic cancer has a five-year survival rate of about 13.7% and accounts for 8.4% of cancer deaths in the U.S.
Opening excerpt (first ~120 words) tap to expand
HealthWatch FDA expands access to pancreatic cancer drug helping patients like Ben Sasse .chip { background-image: url('/fly/bundles/cbsnewscore/images/chip-bgd/chip-bgd-healthwatch.jpg'); } By Kerry Breen Kerry Breen News Editor Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, breaking news and issues including substance use. Read Full Bio Kerry Breen May 1, 2026 / 3:14 PM EDT / CBS News Add CBS News on Google The Food and Drug Administration said it will allow some pancreatic cancer patients to receive access to a promising drug, even before it is officially approved for use. The medication, daraxonrasib, is a pill taken three times a day.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Home - CBSNews.com.
Discussion
0 commentsMore from Home - CBSNews.com
